These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30864501)

  • 1. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.
    Tomasetti C; Montemitro C; Fiengo ALC; Santone C; Orsolini L; Valchera A; Carano A; Pompili M; Serafini G; Perna G; Vellante F; Martinotti G; Giannantonio MD; Kim YK; Nicola MD; Bellomo A; Ventriglio A; Fornaro M; Berardis DD
    Curr Pharm Des; 2019; 25(4):381-387. PubMed ID: 30864501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
    Lener MS; Kadriu B; Zarate CA
    Drugs; 2017 Mar; 77(4):381-401. PubMed ID: 28194724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical overview of NMDA-R antagonists and clinical practice.
    Davoudian PA; Wilkinson ST
    Adv Pharmacol; 2020; 89():103-129. PubMed ID: 32616204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
    Huang YJ; Lane HY; Lin CH
    Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoaminergic system and depression.
    Perez-Caballero L; Torres-Sanchez S; Romero-López-Alberca C; González-Saiz F; Mico JA; Berrocoso E
    Cell Tissue Res; 2019 Jul; 377(1):107-113. PubMed ID: 30627806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
    Chaki S; Ago Y; Palucha-Paniewiera A; Matrisciano F; Pilc A
    Neuropharmacology; 2013 Mar; 66():40-52. PubMed ID: 22640631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back.
    Murck H
    J Psychiatr Res; 2013 Jul; 47(7):955-65. PubMed ID: 23541145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of astrocytic connexins in the regulation of extracellular glutamate levels: implication for the treatment of major depressive episodes].
    Portal B; Guiard BP
    Biol Aujourdhui; 2020; 214(3-4):71-83. PubMed ID: 33357364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.
    Artigas F; Celada P; Bortolozzi A
    Eur Neuropsychopharmacol; 2018 Apr; 28(4):457-482. PubMed ID: 29525411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel drug developmental strategies for treatment-resistant depression.
    Borbély É; Simon M; Fuchs E; Wiborg O; Czéh B; Helyes Z
    Br J Pharmacol; 2022 Mar; 179(6):1146-1186. PubMed ID: 34822719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.
    Papakostas GI; Ionescu DF
    Mol Psychiatry; 2015 Oct; 20(10):1142-50. PubMed ID: 26148812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
    Szakacs R; Janka Z; Kalman J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate-Based Drug Discovery for Novel Antidepressants.
    Pałucha-Poniewiera A; Pilc A
    Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.